Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News

Search
Tags
Duchenne News Tags
Antisense Therapeutics Astellas Avidity Biosciences Dyne Edgewise Entrada Therapeutics FibroGen Italfarmaco NS Pharma PepGen Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Solid Biosciences Wave Life Sciences
September 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44...
Read More
August 30, 2023

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

FibroGen announces topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne.
Read More
August 7, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne

Entrada announces authorization for its CTIMP for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44
Read More
July 21, 2023

PepGen Shares 2023 Q2 Newsletter

PepGen shares their 2023 Q2 newsletter
Read More
July 5, 2023

Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne and Receives Priority Review

Italfarmaco announces that the FDA has completed filing review and accepted the company’s NDA for Givinostat.
Read More
June 27, 2023

Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy

Edgewise Therapeutics announces positive 12-month topline results from the ongoing ARCH study for Becker muscular dystrophy
Read More
June 22, 2023

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

Sarepta announces U.S. Food and Drug Administration accelerated approval of ELEVIDYS.
Read More
June 20, 2023

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

Santhera announces that it has signed an exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals.
Read More
June 8, 2023

Sarepta Provides Update for SRP-9001-303: ENVISION study enrollment in U.S.

Sarepta shares enrollment updates for SRP-9001-303 study.
Read More
June 8, 2023

Antisense Announces First Patient Dosed in ATL1102 Phase IIb Duchenne Trial

Antisense Therapeutics announces that recruitment has commenced in the multicentre double-blind, placebo-controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne.
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Experience the magic of camp promise

    Complete applications due April 3, 2023.
    Apply Now